Loading...
Market
Story
GSK Agrees to $2.2 Billion Settlement Covering 93% of U.S. Zantac Lawsuits
Oct 9, 2024, 05:33 PM
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 U.S. state court cases related to its heartburn medication Zantac. The settlements encompass agreements with ten plaintiff firms, representing 93% of the product liability cases pending against the company, and are expected to be finalized by the first half of 2025. GSK will record a charge of £1.8 billion in its Q3 2024 results to account for the settlements. Additionally, the company has resolved a Qui Tam complaint for $70 million. Despite the settlements, GSK maintains that there is no consistent evidence that ranitidine, the active ingredient in Zantac, increases the risk of cancer.
View original story
Similar markets
Less than $2 billion • 25%
$2 billion to $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 90% • 25%
90% to 95% • 25%
95% to 99% • 25%
100% • 25%
Less than 3 • 25%
3 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%
Less than $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
$3 billion to $3.5 billion • 25%
More than $3.5 billion • 25%
GSK • 25%
Sanofi • 25%
Pfizer • 25%
Other • 25%
Decrease by more than 10% • 25%
Decrease by 5% to 10% • 25%
Decrease by less than 5% • 25%
No significant change • 25%